KRAS and lung cancer: These authors demonstrated that using the dual AURKA and AURKB inhibitor, AI II, reduces growth, viability, and anchorage-independent growth in a KRAS-dependent manner, showing that AURKA and AURKB are promising targets for KRAS-induced lung cancer therapy.